Mimedx Group Inc Stock Price, News & Analysis

MiMedx (Nasdaq: MDXG) announced on October 6, 2025 the launch of EPIXPRESS, a next‑generation lyophilized human placental allograft added to its Advanced Wound Care portfolio.

EPIXPRESS is a PURION®‑processed, thick tri‑layer product that adds fenestrations to improve fluid movement versus EPIEFFECT and is intended for acute and chronic hard‑to‑heal wounds including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), deep or tunneling wounds, and wounds requiring suture fixation.

The company characterized the product as an organically developed, market‑driven innovation designed to expand clinician treatment options.

MIMEDX (NASDAQ:MDXG) has announced its participation in the Symposium on Advanced Wound Care (SAWC) Fall meeting from September 3-6, 2025 in Las Vegas. The company will host a sponsored lunch symposium titled "Change is Inevitable: Mastering the Art of Wound Healing in an Evolving Landscape" on September 4, 2025.

MIMEDX will showcase its advanced wound care portfolio at booth 511 and present six clinical and scientific posters focusing on various aspects of amniotic tissue applications, including pigment restoration, wound healing mechanisms, and cost-effectiveness analysis of placental allografts.

MIMEDX (NASDAQ:MDXG) has announced its participation in two upcoming investor conferences in New York. The company's senior management will present at the Cantor Global Healthcare Conference on September 3, 2025, featuring a fireside chat at 1:35 PM ET. Additionally, they will attend the Lake Street BIG9 Best Ideas Growth Conference on September 11, 2025, where they will participate in one-on-one meetings.

Interested investors can arrange meetings with MIMEDX management through their Cantor or Lake Street representatives.

MIMEDX (NASDAQ:MDXG) reported record-breaking Q2 2025 results with net sales of $99 million, marking a 13% year-over-year growth. The company achieved GAAP net income of $10 million ($0.06 per diluted share) and Adjusted EBITDA of $24 million (25% of net sales).

Growth was driven by strong performance in both segments: Wound product sales increased 12%, supported by CELERA™ and EMERGE™ products, while Surgical products grew 15%, with notable contributions from AMNIOFIX®, AMNIOEFFECT®, and HELIOGEN™. The company ended the quarter with $119 million in cash, up $12 million.

Based on strong performance, MIMEDX raised its 2025 guidance, now expecting low double-digit net sales growth and Adjusted EBITDA margin above 20%.

MIMEDX (NASDAQ:MDXG) has announced a strategic collaboration with Vaporox, establishing co-promotion and co-marketing of MIMEDX's placental allograft portfolio alongside Vaporox's Vaporous Hyperoxia Therapy (VHT) device. The partnership includes a strategic investment by MIMEDX in Vaporox and exclusive rights for potential acquisition discussions.

Vaporox's FDA-cleared VHT device combines ultrasonic mist and concentrated oxygen to treat nine types of chronic wounds, including Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers. Clinical studies have shown wound healing rates exceeding 80% at 20 weeks when VHT is combined with standard wound care, with promising results when used with MIMEDX's EPIFIX® products.

MIMEDX (NASDAQ: MDXG) has scheduled its second quarter 2025 earnings conference call for July 30, 2025. The company will release its Q2 2025 operating and financial results after market close, followed by a management-hosted webcast and conference call at 4:30 p.m. Eastern Time.

Investors can access the call through the webcast or by phone using dedicated U.S. (877-407-6184) and international (201-389-0877) numbers with conference ID 13754722. A replay will be available on the company's website for approximately 30 days after the event.

MIMEDX (NASDAQ:MDXG) has responded to CMS's proposed CY 2026 Physician Fee Schedule changes regarding skin substitute reimbursement. The new proposal suggests replacing the current ASP methodology with a fixed price of $125.38 per square centimeter for all skin substitutes.

The reform aims to address the dramatic increase in Medicare spending on skin substitutes, which surged from $1.5 billion in 2022 to nearly $10 billion in 2024. CEO Joseph H. Capper supports the reform, noting it will help combat fraud and unsavory business practices in the market.

The changes, along with the WISeR model and pending LCDs, are scheduled for implementation on January 1, 2026. MIMEDX expects to maintain its competitive position due to its product capabilities and clinical evidence.

MIMEDX (NASDAQ: MDXG) has announced its senior management's participation in three upcoming investor conferences. The company will attend the Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis on May 28, 2025, the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 11, 2025, and the virtual Northland Capital Growth Conference on June 25, 2025. All events will feature one-on-one sessions with management. Interested investors can arrange meetings through their respective conference representatives.

MIMEDX (NASDAQ: MDXG) announced its participation in the upcoming BofA Securities 2025 Healthcare Conference in Las Vegas, NV. The Company's senior management team is scheduled to present on Tuesday, May 13, 2025, at 5:15 p.m. PDT. Interested investors who wish to meet with MIMEDX's senior management during the conference should contact their Bank of America representative to arrange meetings.